Search

Your search keyword '"Hilberg, Ole"' showing total 930 results
Start Over Author "Hilberg, Ole"
930 results on '"Hilberg, Ole"'

52. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”

Author

Chen, Wenjia, primary, Tran, Trung N., additional, Sadatsafavi, Mohsen, additional, Murray, Ruth B., additional, Boon Wong, Nigel Chong, additional, Ali, Nasloon, additional, Ariti, Con, additional, Bulathsinhala, Lakmini, additional, Garcia Gil, Esther, additional, FitzGerald, J. Mark, additional, Alacqua, Marianna, additional, Al-Ahmad, Mona, additional, Altraja, Alan, additional, Al-Lehebi, Riyad, additional, Bhutani, Mohit, additional, Bjermer, Leif, additional, Bjerrum, Anne-Sofie, additional, Bourdin, Arnaud, additional, von Bülow, Anna, additional, Busby, John, additional, Canonica, Giorgio Walter, additional, Carter, Victoria, additional, Christoff, George C., additional, Cosio, Borja G., additional, Costello, Richard W., additional, Fonseca, João A., additional, Gibson, Peter G., additional, Yoo, Kwang Ha, additional, Heaney, Liam G., additional, Heffler, Enrico, additional, Hew, Mark, additional, Hilberg, Ole, additional, Hoyte, Flavia, additional, Iwanaga, Takashi, additional, Jackson, David J., additional, Jones, Rupert C., additional, Koh, Mariko Siyue, additional, Kuna, Piotr, additional, Larenas-Linnemann, Désirée, additional, Lehmann, Sverre, additional, Lehtimäki, Lauri, additional, Lyu, Juntao, additional, Mahboub, Bassam, additional, Maspero, Jorge, additional, Menzies-Gow, Andrew N., additional, Newell, Anthony, additional, Sirena, Concetta, additional, Papadopoulos, Nikolaos G., additional, Papaioannou, Andriana I., additional, Perez-de-Llano, Luis, additional, Perng (Steve), Diahn-Warng, additional, Peters, Matthew J., additional, Pfeffer, Paul E., additional, Porsbjerg, Celeste M., additional, Popov, Todor A., additional, Rhee, Chin Kook, additional, Salvi, Sundeep, additional, Taillé, Camille, additional, Taube, Christian, additional, Torres-Duque, Carlos A., additional, Ulrik, Charlotte, additional, Ra, Seung Won, additional, Wang, Eileen, additional, Wechsler, Michael E., additional, and Price, David B., additional

Published
2024
Full Text
View/download PDF

62. BASELINE CHARACTERISTICS OF PATIENTS WITH ASTHMA AND PRIOR SYSTEMIC CORTICOSTEROID USE INITIATING DUPILUMAB IN REAL-WORLD CLINICAL PRACTICE IN THE RAPID REGISTRY

Author

LUGOGO, NJIRA L, primary, HEFFLER, ENRICO, additional, PLAZA, VICENTE, additional, HILBERG, OLE, additional, XIA, CHANGMING, additional, NASH, SCOTT, additional, PANDIT-ABID, NAMI, additional, JACOB-NARA, JUBY A, additional, SACKS, HARRY, additional, ROWE, PAUL J, additional, DENIZ, YAMO, additional, HARDIN, MEGAN, additional, and SOLER, XAVIER, additional

Published
2023
Full Text
View/download PDF

63. Tobacco exposure and efficacy of biologic therapy in patients with severe asthma: A nationwide study from the Danish Severe Asthma Register

Author

Soendergaard, Marianne Baastrup, primary, Hansen, Susanne, additional, Bjerrum, Anne-Sofie, additional, von Bülow, Anna, additional, Julius Haakansson, Kjell Erik, additional, Hilberg, Ole, additional, Ingebrigtsen, Truls Sylvan, additional, Johnsen, Claus Rikard, additional, Lock-Johansson, Sofie, additional, Rasmussen, Linda Makowska, additional, Schmid, Johannes Martin, additional, Ulrik, Charlotte Suppli, additional, and Porsbjerg, Celeste, additional

Published
2023
Full Text
View/download PDF

69. Baseline characteristics of patients with asthma and prior systemic corticosteroid use in the RAPID (dupilumab) registry

Author

Lugogo, Njira L., primary, Heffler, Enrico Marco, additional, Plaza, Vicente, additional, Hilberg, Ole, additional, Xia, Changming, additional, Nash, Scott, additional, Pandit-Abid, Nami, additional, Jacob-Nara, Juby A., additional, Sacks, Harry, additional, Rowe, Paul J., additional, Deniz, Yamo, additional, Hardin, Megan, additional, and Soler, Xavier, additional

Published
2023
Full Text
View/download PDF

73. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

Author

Hughes, Rod, primary, Rapsomaniki, Eleni, additional, Bansal, Aruna T., additional, Vestbo, Jørgen, additional, Price, David, additional, Agustí, Alvar, additional, Beasley, Richard, additional, Fageras, Malin, additional, Alacqua, Marianna, additional, Papi, Alberto, additional, Müllerová, Hana, additional, Reddel, Helen K., additional, Olmo, Ricardo del, additional, Anderson, Gary, additional, Reddel, Helen, additional, Rabahi, Marcelo, additional, McIvor, Andrew, additional, Sadatsafavi, Mohsen, additional, Weinreich, Ulla, additional, Burgel, Pierre-Régis, additional, Devouassoux, Gilles, additional, Inoue, Hiromasa, additional, Rendon, Adrián, additional, van den Berge, Maarten, additional, García-Navarro, Alvar Agusti, additional, Faner, Rosa, additional, Olaguibel Rivera, José, additional, Janson, Christer, additional, Bilińska-Izydorczyk, Magdalena, additional, Fagerås, Malin, additional, Fihn-Wikander, Titti, additional, Franzén, Stefan, additional, Keen, Christina, additional, Ostridge, Kristoffer, additional, Chalmers, James, additional, Harrison, Timothy, additional, Pavord, Ian, additional, Azim, Adnan, additional, Belton, Laura, additional, Blé, Francois-Xavier, additional, Erhard, Clement, additional, Gairy, Kerry, additional, Hughes, Rod, additional, Lassi, Glenda, additional, Scott, Ian Christopher, additional, Chipps, Bradley, additional, Christenson, Stephanie, additional, Make, Barry, additional, Tomaszewski, Erin, additional, Benhabib, Gabriel, additional, Ruiz, Xavier Bocca, additional, Lisanti, Raul Eduardo, additional, Marino, Gustavo, additional, Mattarucco, Walter, additional, Nogueira, Juan, additional, Parody, Maria, additional, Pascale, Pablo, additional, Rodriguez, Pablo, additional, Silva, Damian, additional, Svetliza, Graciela, additional, Victorio, Carlos F., additional, Rolon, Roxana Willigs, additional, Yañez, Anahi, additional, Baines, Stuart, additional, Bowler, Simon, additional, Bremner, Peter, additional, Bull, Sheetal, additional, Carroll, Patrick, additional, Chaalan, Mariam, additional, Farah, Claude, additional, Hammerschlag, Gary, additional, Hancock, Kerry, additional, Harrington, Zinta, additional, Katsoulotos, Gregory, additional, Kim, Joshua, additional, Langton, David, additional, Lee, Donald, additional, Peters, Matthew, additional, Prassad, Lakshman, additional, Sajkov, Dimitar, additional, Santiago, Francis, additional, Simpson, Frederick Graham, additional, Tai, Sze, additional, Thomas, Paul, additional, Wark, Peter, additional, Cançado, José Eduardo Delfini, additional, Cunha, Thúlio, additional, Lima, Marina, additional, Cardoso, Alexandre Pinto, additional, FitzGerald, J. Mark, additional, Anees, Syed, additional, Bertley, John, additional, Bell, Alan, additional, Cheema, Amarjit, additional, Chouinard, Guy, additional, Csanadi, Michael, additional, Dhar, Anil, additional, Dhillon, Ripple, additional, Kanawaty, David, additional, Kelly, Allan, additional, Killorn, William, additional, Landry, Daniel, additional, Luton, Robert, additional, Mandhane, Piushkumar, additional, Pek, Bonavuth, additional, Petrella, Robert, additional, Stollery, Daniel, additional, Wang, Chen, additional, Chen, Meihua, additional, Chen, Yan, additional, Gu, Wei, additional, Christopher Hui, Kim Ming, additional, Li, Manxiang, additional, Li, Shiyue, additional, Lijun, Ma, additional, Qin, Guangyue, additional, Song, Weidong, additional, Tan, Wei, additional, Tang, Yijun, additional, Wang, Tan, additional, Wen, Fuqiang, additional, Wu, Feng, additional, Xiang, PingChao, additional, Xiao, Zuke, additional, Xiong, Shengdao, additional, Yang, Jinghua, additional, Yang, Jingping, additional, Zhang, Caiqing, additional, Zhang, Min, additional, Zhang, Ping, additional, Zhang, Wei, additional, Zheng, Xiaohe, additional, Zhu, Dan, additional, Bueno, Carlos Matiz, additional, Grimaldos, Fabio Bolivar, additional, Arboleda, Alejandra Cañas, additional, de Salazar, Dora Molina, additional, Bendstrup, Elisabeth, additional, Hilberg, Ole, additional, Kjellerup, Carsten, additional, Raherison, Chantal, additional, Bonniaud, Philippe, additional, Brun, Olivier, additional, Chouaid, Christos, additional, Couturaud, Francis, additional, de Blic, Jacques, additional, Debieuvre, Didier, additional, Delsart, Dominique, additional, Demaegdt, Axelle, additional, Demoly, Pascal, additional, Deschildre, Antoine, additional, Egron, Carole, additional, Falchero, Lionel, additional, Goupil, François, additional, Kessler, Romain, additional, Le Roux, Pascal, additional, Mabire, Pascal, additional, Mahay, Guillaume, additional, Martinez, Stéphanie, additional, Melloni, Boris, additional, Moreau, Laurent, additional, Riviere, Emilie, additional, Roux-Claudé, Pauline, additional, Soulier, Michel, additional, Vignal, Guillaume, additional, Yaici, Azzedine, additional, Bals, Robert, additional, Aries, Sven Philip, additional, Beck, Ekkehard, additional, Deimling, Andreas, additional, Feimer, Jan, additional, Grimm-Sachs, Vera, additional, Groth, Gesine, additional, Herth, Felix, additional, Hoheisel, Gerhard, additional, Kanniess, Frank, additional, Lienert, Thomas, additional, Mronga, Silke, additional, Reinhardt, Jörg, additional, Schlenska, Christian, additional, Stolpe, Christoph, additional, Teber, Ishak, additional, Timmermann, Hartmut, additional, Ulrich, Thomas, additional, Velling, Peter, additional, Wehgartner-Winkler, Sabina, additional, Welling, Juergen, additional, Winkelmann, Ernst-Joachim, additional, Barbetta, Carlo, additional, Braido, Fulvio, additional, Cardaci, Vittorio, additional, Clini, Enrico Maria, additional, Costantino, Maria Teresa, additional, Cuttitta, Giuseppina, additional, di Gioacchino, Mario, additional, Fois, Alessandro, additional, Foschino-Barbaro, Maria Pia, additional, Gammeri, Enrico, additional, Inchingolo, Riccardo, additional, Lavorini, Federico, additional, Molino, Antonio, additional, Nucera, Eleonora, additional, Patella, Vincenzo, additional, Pesci, Alberto, additional, Ricciardolo, Fabio, additional, Rogliani, Paola, additional, Sarzani, Riccardo, additional, Vancheri, Carlo, additional, Vincenti, Rigoletta, additional, Endo, Takeo, additional, Fujita, Masaki, additional, Hara, Yu, additional, Horiguchi, Takahiko, additional, Hosoi, Keita, additional, Ide, Yumiko, additional, Inomata, Minehiko, additional, Inoue, Koji, additional, Inoue, Sumito, additional, Kato, Motokazu, additional, Kawasaki, Masayuki, additional, Kawayama, Tomotaka, additional, Kita, Toshiyuki, additional, Kobayashi, Kanako, additional, Koto, Hiroshi, additional, Nishi, Koichi, additional, Saito, Junpei, additional, Shimizu, Yasuo, additional, Shirai, Toshihiro, additional, Sugihara, Naruhiko, additional, Takahashi, Ken-ichi, additional, Tashimo, Hiroyuki, additional, Tomii, Keisuke, additional, Yamada, Takashi, additional, Yanai, Masaru, additional, Rendon, Adrian, additional, Cerino Javier, Ruth, additional, Domínguez Peregrina, Alfredo, additional, Fernández Corzo, Marco, additional, Montano Gonzalez, Efraín, additional, Ramírez-Venegas, Alejandra, additional, Boersma, Willem, additional, Djamin, R.S., additional, Eijsvogel, Michiel, additional, Franssen, Frits, additional, Goosens, Martijn, additional, Graat-Verboom, Lidwien, additional, Veen, Johannes in 't, additional, Janssen, Rob, additional, Kuppens, Kim, additional, van de Ven, Mario, additional, Bakke, Per, additional, Brunstad, Ole Petter, additional, Einvik, Gunnar, additional, Høines, Kristian Jong, additional, Khusrawi, Alamdar, additional, Oien, Torbjorn, additional, Yoon, Ho Joo, additional, Chang, Yoon-Seok, additional, Cho, Young Joo, additional, Hwang, Yong Il, additional, Kim, Woo Jin, additional, Koh, Young-Il, additional, Lee, Byung-Jae, additional, Lee, Kwan-Ho, additional, Lee, Sang-Pyo, additional, Lee, Yong Chul, additional, Lim, Seong Yong, additional, Min, Kyung Hun, additional, Oh, Yeon-Mok, additional, Park, Choon-Sik, additional, Park, Hae-Sim, additional, Park, Heung-Woo, additional, Rhee, Chin Kook, additional, Yoon, Hyoung-Kyu, additional, García-Navarro, Alvar Agustí, additional, Andújar, Rubén, additional, Anoro, Laura, additional, Buendía García, María, additional, Mozo, Paloma Campo, additional, Campos, Sergio, additional, Casas Maldonado, Francisco, additional, Castilla Martínez, Manuel, additional, Cisneros Serrano, Carolina, additional, Comeche Casanova, Lorena, additional, Corbacho, Dolores, additional, Campo Matías, Felix Del, additional, Echave-Sustaeta, Jose, additional, Corral, Gloria Francisco, additional, Gamboa Setién, Pedro, additional, García Clemente, Marta, additional, Núñez, Ignacio García, additional, García Robaina, Jose, additional, García Salmones, Mercedes, additional, Marín Trigo, Jose Maria, additional, Fernandez, Marta Nuñez, additional, Palomo, Sara Nuñez, additional, Pérez de Llano, Luis, additional, Pueyo Bastida, Ana, additional, Rañó, Ana, additional, Rodríguez González-Moro, José, additional, Reig, Albert Roger, additional, Velasco Garrido, José, additional, Curiac, Dan, additional, Lif-Tiberg, Cornelia, additional, Luts, Anders, additional, Råhlen, Lennart, additional, Rustscheff, Stefan, additional, Adams, Frances, additional, Bradman, Drew, additional, Broughton, Emma, additional, Cosgrove, John, additional, Flood-Page, Patrick, additional, Fuller, Elizabeth, additional, Hartley, David, additional, Hattotuwa, Keith, additional, Jones, Gareth, additional, Lewis, Keir, additional, McGarvey, Lorcan, additional, Morice, Alyn, additional, Pandya, Preeti, additional, Patel, Manish, additional, Roy, Kay, additional, Sathyamurthy, Ramamurthy, additional, Thiagarajan, Swaminathan, additional, Turner, Alice, additional, Wedzicha, Wisia, additional, Wilkinson, Tom, additional, Wilson, Pete, additional, Al-Asadi, Lo’Ay, additional, Anholm, James, additional, Averill, Francis, additional, Bansal, Sandeep, additional, Baptist, Alan, additional, Campbell, Colin, additional, Campos, Michael A., additional, Crook, Gretchen, additional, DeLeon, Samuel, additional, Eid, Alain, additional, Epstein, Ellen, additional, Fritz, Stephen, additional, Harris, Hoadley, additional, Hewitt, Mitzie, additional, Holguin, Fernando, additional, Hudes, Golda, additional, Jackson, Richard, additional, Kaufman, Alan, additional, Kaufman, David, additional, Klapholz, Ari, additional, Krishna, Harshavardhan, additional, Lee, Daria, additional, Lin, Robert, additional, Maselli-Caceres, Diego, additional, Mehta, Vinay, additional, Moy, James N., additional, Nwokoro, Ugo, additional, Parikh, Purvi, additional, Parikh, Sudhir, additional, Perrino, Frank, additional, Ruhlmann, James, additional, Sassoon, Catherine, additional, Settipane, Russell A., additional, Sousa, Daniel, additional, Sriram, Peruvemba, additional, and Wachs, Richard, additional

Published
2023
Full Text
View/download PDF

76. Severe asthma trajectories in adults: findings from the NORDSTAR cohort

Author

von Bülow, Anna, primary, Hansen, Susanne, additional, Sandin, Patrik, additional, Ernstsson, Olivia, additional, Janson, Christer, additional, Lehtimäki, Lauri, additional, Kankaanranta, Hannu, additional, Ulrik, Charlotte, additional, Aarli, Bernt Bøgvald, additional, Geale, Kirk, additional, Tang, Sheila Tuyet, additional, Wolf, Maija, additional, Backer, Vibeke, additional, Hilberg, Ole, additional, Altraja, Alan, additional, Backman, Helena, additional, Lúdvíksdóttir, Dóra, additional, Björnsdóttir, Unnur Steina, additional, Kauppi, Paula, additional, Sandström, Thomas, additional, Sverrild, Asger, additional, Yasinska, Valentyna, additional, Kilpeläinen, Maritta, additional, Dahlén, Barbro, additional, Viinanen, Arja, additional, Bjermer, Leif, additional, Bossios, Apostolos, additional, and Porsbjerg, Celeste, additional

Published
2023
Full Text
View/download PDF

84. Pulmonary Mycobacterium abscessus infection treated in combination with inhaled tigecycline.

Author

Pedersen, Andreas Arnholdt, Fløe, Andreas, Løkke, Anders, and Hilberg, Ole

Abstract

Pulmonary disease caused by Mycobacterium abscessus is difficult to treat, as there is currently no reliable evidence-based treatment. Treatment is long, complex and has many side effects. In this case, we report a patient with treatment-refractory pulmonary M. abscessus disease, treated with inhaled tigecycline. Treatment with inhaled tigecycline lasted 15 months with comparably limited side effects. There were no positive mycobacterial cultures in the follow-up period of 2 years. Inhaled tigecycline is an option in the treatment of pulmonary M. abscessus when first-line treatment fails. Additional research should investigate this further. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

88. Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both

Author

Pfeffer, Paul E., primary, Ali, Nasloon, additional, Murray, Ruth, additional, Ulrik, Charlotte, additional, Tran, Trung N., additional, Maspero, Jorge, additional, Peters, Matthew, additional, Christoff, George C., additional, Sadatsafavi, Mohsen, additional, Torres‐Duque, Carlos A., additional, Altraja, Alan, additional, Lehtimäki, Lauri, additional, Papadopoulos, Nikolaos G., additional, Salvi, Sundeep, additional, Costello, Richard W., additional, Cushen, Breda, additional, Heffler, Enrico, additional, Iwanaga, Takashi, additional, Al‐Ahmad, Mona, additional, Larenas‐Linnemann, Désirée, additional, Kuna, Piotr, additional, Fonseca, João A., additional, Al‐Lehebi, Riyad, additional, Rhee, Chin Kook, additional, Perez‐de‐Llano, Luis, additional, Perng Steve, Diahn‐Warng, additional, Mahboub, Bassam, additional, Wang, Eileen, additional, Goh, Celine, additional, Lyu, Juntao, additional, Newell, Anthony, additional, Alacqua, Marianna, additional, Belevskiy, Andrey S., additional, Bhutani, Mohit, additional, Bjermer, Leif, additional, Bjornsdottir, Unnur, additional, Bourdin, Arnaud, additional, Bulow, Anna von, additional, Busby, John, additional, Canonica, Giorgio Walter, additional, Cosio, Borja G., additional, Dorscheid, Delbert R., additional, Muñoz‐Esquerre, Mariana, additional, FitzGerald, J. Mark, additional, Gil, Esther Garcia, additional, Gibson, Peter G., additional, Heaney, Liam G., additional, Hew, Mark, additional, Hilberg, Ole, additional, Hoyte, Flavia, additional, Jackson, David J., additional, Koh, Mariko Siyue, additional, Ko, Hsin‐Kuo Bruce, additional, Lee, Jae Ha, additional, Lehmann, Sverre, additional, Chaves Loureiro, Cláudia, additional, Lúðvíksdóttir, Dóra, additional, Menzies‐Gow, Andrew N., additional, Mitchell, Patrick, additional, Papaioannou, Andriana I., additional, Popov, Todor A., additional, Porsbjerg, Celeste M., additional, Salameh, Laila, additional, Sirena, Concetta, additional, Taillé, Camille, additional, Taube, Christian, additional, Tohda, Yuji, additional, Wechsler, Michael E., additional, and Price, David B., additional

Published
2023
Full Text
View/download PDF

90. Renin–angiotensin–system inhibitors and the risk of exacerbations in chronic obstructive pulmonary disease: a nationwide registry study

Author

Vilstrup, Frida, primary, Heerfordt, Christian Kjer, additional, Kamstrup, Peter, additional, Hedsund, Caroline, additional, Biering-Sørensen, Tor, additional, Sørensen, Rikke, additional, Kolekar, Shailesh, additional, Hilberg, Ole, additional, Pedersen, Lars, additional, Lund, Thomas Kromann, additional, Klausen, Tobias Wirenfeldt, additional, Skaarup, Kristoffer Grundtvig, additional, Eklöf, Josefin, additional, Sivapalan, Pradeesh, additional, and Jensen, Jens-Ulrik Stæhr, additional

Published
2023
Full Text
View/download PDF

91. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

Author

Louis, Renaud, primary, Harrison, Tim W., additional, Chanez, Pascal, additional, Menzella, Francesco, additional, Philteos, George, additional, Cosio, Borja G., additional, Lugogo, Njira L., additional, de Luiz, Gustavo, additional, Burden, Annie, additional, Adlington, Timothy, additional, Keeling, Nanna, additional, Kwiatek, Justin, additional, Garcia Gil, Esther, additional, Pohl, Wolfgang, additional, Doberer, Daniel, additional, Martinot, Jean Benoit, additional, Deschampheleire, Maud, additional, Himpe, Ulrike, additional, Chapman, Kenneth, additional, Cheema, Amarjit, additional, Dorscheid, Delbert, additional, Ramsey, Clare, additional, Rolf, Jeffrey, additional, Walker, Brandie, additional, Olivenstein, Ronald, additional, Poirier, Claude, additional, Larivee, Pierre, additional, Bjerrum, Anne Sofie, additional, Titlestad, Ingrid, additional, Hilberg, Ole, additional, Kilpeläinen, Maritta, additional, Bonniaud, Philippe, additional, Taillé, Camille, additional, Tiotiu, Iuliana-Angelica, additional, Girodet, Pierre-Olivier, additional, Blanc, François-Xavier, additional, Pradelli, Johana, additional, Didier, Alain, additional, Nocent Ejnaini, Cecilia, additional, Deslee, Gaetan, additional, Pison, Christophe, additional, Douadi, Youcef, additional, Mahay, Guillaume, additional, Devouassoux, Gilles, additional, Melloni, Boris, additional, Roux, Pauline-Marie, additional, Bourdin, Arnaud, additional, Fry, Stephanie, additional, Schaum, Thomas, additional, Schulz, Christian, additional, Skowasch, Dirk, additional, Taube, Christian, additional, Welte, Tobias, additional, Gleiber, Wolfgang, additional, Brehler, Randolf, additional, Schreiber, Jens, additional, Schuette, Wolfgang, additional, Kronsbein, Juliane, additional, Bonnet, Reiner, additional, Beck, Ekkehard, additional, Lacedonia, Donato, additional, Senna, Gianenrico, additional, Caruso, Cristiano, additional, Crimi, Nunzio, additional, Blasi, Francesco, additional, Santus, Pierachille, additional, Canonica, Giorgio Walter, additional, Guarnieri, Gabriella, additional, Pelaia, Girolamo, additional, Milanese, Manlio, additional, Micheletto, Claudio, additional, Corsico, Angelo Guido, additional, Scichilone, Nicola, additional, Spadaro, Giuseppe, additional, Langeveld, Bas, additional, Holters, Jurgen, additional, Willem van den Berg, Jan, additional, Smit, Arthur, additional, Conemans, Lennart, additional, van Veen, Helena, additional, Staaks, Gerald, additional, Lehmann, Sverre, additional, Echave-Sustaeta, Jose Maria, additional, Ribas, Christian Domingo, additional, de Luiz Martinez, Gustavo, additional, Gonzalez Perez, Ruperto, additional, Garcia Rivero, Juan Luis, additional, Gall, Xavier Muñoz, additional, Soto Campos, Jose Gregorio, additional, Mozo, Paloma Campo, additional, Pan, Carmen Vidal, additional, Fernandez, Ana Gomez-Bastero, additional, Tellez, Sergio Campos, additional, Rivera, Carlos Martinez, additional, Bobolea, Irina Diana, additional, Guerrero, Raquel Morillo, additional, Garcia, Ismael Ali, additional, Rodriguez Hermosa, Juan Luis, additional, Stenfors, Nikolai, additional, Tunsäter, Alf, additional, Curiac, Dan, additional, von Garnier, Christophe, additional, Leuppi, Joerg, additional, Schmid-Grendelmeier, Peter, additional, Nasser, Shuaib, additional, Chaudhuri, Rekha, additional, Nordstrom, Monica, additional, Saralaya, Dinesh, additional, Pfeffer, Paul, additional, Mansur, Adel, additional, Short, Philip, additional, Wenzel, Sally, additional, Cherry, William Brett, additional, Zafra, Heidi, additional, Gonzalez, Erika, additional, Soong, Weily, additional, Davis, Benjamin, additional, Kao, Neil, additional, Hussain, Iftikhar, additional, Maselli Caceres, Diego Jose, additional, Harris, James, additional, Calhoun, William, additional, Rodicio, Ileana, additional, Kaufman, David, additional, Moss, Mark, additional, Sztejman, Eric, additional, DeLeon, Samuel, additional, Sumino, Kaharu, additional, Kashyap, Ravindra, additional, Leflein, Jeffrey, additional, Hajal, Rizan, additional, Fakih, Faisal, additional, Hill, David, additional, Lin, Robert, additional, Jarratt, Mikell, additional, Subramaniam, Vijay, additional, Sussman, Robert, additional, Mumneh, Nayla, additional, Reibman, Joan, additional, Darveaux, Jared, additional, Tan, Ricardo, additional, Tanus, Tonny, additional, Sikand, Vinay, additional, Marshall, Gailen, additional, Mehta, Hemalini, additional, Cole, Jeremy, additional, Goodman, Brad, additional, Goss, Deborah, additional, Bardelas, Jose, additional, Milstone, Aaron, additional, Mehta, Vinay, additional, Clore, Lee, additional, Millard, Mark, additional, Palumbo, Michael, additional, Puppala, Dileep, additional, Leong, Mila, additional, Prenner, Bruce, additional, Robinette, Emory, additional, Heidarian Raissy, Hengameh, additional, Fost, David, additional, Pleskow, Warren, additional, Marcus, Michael, additional, Ilowite, Jonathan, additional, Moore, Wendy, additional, Steven, Gary, additional, De la Cruz, Luis, additional, Chupp, Geoffrey, additional, Berger, William, additional, Randolph, Christopher, additional, Holguin, Fernando, additional, Kureishy, Shahrukh, additional, and Campbell, Edward, additional

Published
2023
Full Text
View/download PDF

92. Severe asthma trajectories in adults : findings from the NORDSTAR cohort

Author

von Bülow, Anna, Hansen, Susanne, Sandin, Patrik, Ernstsson, Olivia, Janson, Christer, Lehtimäki, Lauri, Kankaanranta, Hannu, Ulrik, Charlotte, Aarli, Bernt Bøgvald, Geale, Kirk, Tang, Sheila Tuyet, Wolf, Maija, Backer, Vibeke, Hilberg, Ole, Altraja, Alan, Backman, Helena, Lúdvíksdóttir, Dóra, Björnsdóttir, Unnur Steina, Kauppi, Paula, Sandström, Thomas, Sverrild, Asger, Yasinska, Valentyna, Kilpeläinen, Maritta, Dahlén, Barbro, Viinanen, Arja, Bjermer, Leif, Bossios, Apostolos, Porsbjerg, Celeste, von Bülow, Anna, Hansen, Susanne, Sandin, Patrik, Ernstsson, Olivia, Janson, Christer, Lehtimäki, Lauri, Kankaanranta, Hannu, Ulrik, Charlotte, Aarli, Bernt Bøgvald, Geale, Kirk, Tang, Sheila Tuyet, Wolf, Maija, Backer, Vibeke, Hilberg, Ole, Altraja, Alan, Backman, Helena, Lúdvíksdóttir, Dóra, Björnsdóttir, Unnur Steina, Kauppi, Paula, Sandström, Thomas, Sverrild, Asger, Yasinska, Valentyna, Kilpeläinen, Maritta, Dahlén, Barbro, Viinanen, Arja, Bjermer, Leif, Bossios, Apostolos, and Porsbjerg, Celeste

Abstract

Background There is limited evidence on the pathways leading to severe asthma and we are presently unable to effectively predict the progression of the disease. We aimed to describe the longitudinal trajectories leading to severe asthma and to describe clinical events preceding disease progression in a nationwide population of patients with severe asthma. Methods We conducted an observational study based on Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform. We identified adult patients with severe asthma in 2018 according to the European Respiratory Society/American Thoracic Society definition and used latent class analysis to identify trajectories of asthma severity over a 10-year retrospective period from 2018. Results Among 169 128 asthma patients, we identified 4543 severe asthma patients. We identified four trajectories of severe asthma that were labelled as: trajectory 1 “consistently severe asthma” (n=389 (8.6%)), trajectory 2 “gradual onset severe asthma” (n=942 (20.7%)), trajectory 3 “intermittent severe asthma” (n=1685 (37.1%)) and trajectory 4 “sudden onset severe asthma” (n=1527 (33.6%)). “Consistently severe asthma” had a higher daily inhaled corticosteroid dose and more prevalent osteoporosis compared with the other trajectories. Patients with “gradual onset severe asthma” and “sudden onset severe asthma” developed type 2-related comorbidities concomitantly with development of severe asthma. In the latter group, this primarily occurred within 1–3 years preceding onset of severe asthma. Conclusions Four distinct trajectories of severe asthma were identified illustrating different patterns of progression of asthma severity. This may eventually enable the development of better preventive management strategies in severe asthma.

Published
2023
Full Text
View/download PDF

93. The Association Between Cognitive Functions and Psychological Factors in Patients with Severe COPD

Author

Hansen,Kristina Kock, Hilberg,Ole, Jensen,Hanne Irene, Løkke,Anders, Farver-Vestergaard,Ingeborg, Hansen,Kristina Kock, Hilberg,Ole, Jensen,Hanne Irene, Løkke,Anders, and Farver-Vestergaard,Ingeborg

Abstract

Kristina Kock Hansen,1,2 Ole Hilberg,1,2 Hanne Irene Jensen,2,3 Anders Løkke,1,2 Ingeborg Farver-Vestergaard2,4 1Department of Respiratory Diseases, Lillebaelt Hospital, Vejle, University Hospital of Southern Denmark, Denmark; 2Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; 3Department of Anaesthesiology and Intensive Care, Lillebaelt Hospital, Vejle, University Hospital of Southern Denmark, Denmark; 4Department of Medicine, Lillebaelt Hospital, Vejle, University Hospital of Southern Denmark, DenmarkCorrespondence: Kristina Kock Hansen, Department of Respiratory Diseases, Lillebaelt Hospital, Vejle, University Hospital of Southern Denmark, Beriderbakken 4, Vejle, 7100, Denmark, Tel +45 20189828, Email kristina.kock.hansen2@rsyd.dkPurpose: Patients with COPD experience anxiety, depression, and stress more frequently than in the age and gender-matched general population. This cross-sectional study aimed to examine the relationship between cognitive functions and the psychological factors of anxiety, depression and stress among patients with COPD.Patients and Methods: Between January 2021 and January 2023, patients with severe COPD were recruited, along with age-matched controls. Participants completed the Hospital Anxiety and Depression Scale (HADS) and the Perceived Stress Scale (PSS). The Montreal Cognitive Assessment (MoCA), a continuous reaction time test (CRT), and a driving simulator were used to assess cognitive impairment. Hierarchical multiple linear regression analyses were used to explain the variance of the correlations.Results: In total, 80 patients (mean age = 64yrs) and 22 controls (mean age = 61yrs) participated in the study. Patients reported significantly higher levels of psychological symptoms compared to the controls (p ≤ 0.001). We found no differences in anxiety (p = 0.31), depression (p = 0.66) and stress (p = 0.37) between patients with and without cognitive impairment. However, stress showed to be a

Published
2023

94. The Association Between Cognitive Functions and Psychological Factors in Patients with Severe COPD [Corrigendum]

Author

Hansen,Kristina Kock, Hilberg,Ole, Jensen,Hanne Irene, Løkke,Anders, Farver-Vestergaard,Ingeborg, Hansen,Kristina Kock, Hilberg,Ole, Jensen,Hanne Irene, Løkke,Anders, and Farver-Vestergaard,Ingeborg

Abstract

Hansen KK, Hilberg O, Jensen HI, Løkke A, Farver-Vestergaard I. Int J Chron Obstruct Pulmon Dis. 2023;18:2065-2078. Kristina Kock Hansen1,2, Ole Hilberg1,2, Hanne Irene Jensen2,3, Anders Løkke1,2, Ingeborg Farver-Vestergaard2,4 1Department of Respiratory Diseases, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark 2Department of Regional Health Research, University of Southern Denmark, Odense, Denmark 3Department of Anaesthesiology and Intensive Care, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark 4Department of Medicine, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark Correspondence: Kristina Kock Hansen, Department of Respiratory Diseases, Lillebaelt Hospital, Vejle, University Hospital of Southern Denmark, Beriderbakken 4, Vejle, 7100, Denmark, Tel +45 20189828, Email kristina.kock.hansen2@rsyd.dk In Table 2 on page 2070, the values of modified Medical Research Council dyspnea scale (mMRC) in the CI group: 4 (3-4) and in the No CI group: 3 (2-4) should read CI group: 3 (2-3) and No CI group: 2 (1-3). The changes above have no impact on the results of the study. The authors apologize for these errors.

Published
2023

95. Beyond direct costs:individual and societal financial burden of asthma in young adults in a Danish nationwide study

Author

Håkansson, Kjell Erik Julius, Løkke, Anders, Ibsen, Rikke, Hilberg, Ole, Backer, Vibeke, Ulrik, Charlotte Suppli, Håkansson, Kjell Erik Julius, Løkke, Anders, Ibsen, Rikke, Hilberg, Ole, Backer, Vibeke, and Ulrik, Charlotte Suppli

Abstract

Introduction As a common chronic disease seen across all ages, asthma has the potential to incur high societal and individual costs from both direct healthcare costs and loss of productivity. Most previous studies use smaller, selected populations to assess the cost of asthma, possibly reducing generalisability. We, therefore, aimed to assess the total, nationwide economic burden of asthma by severity from both an individual and a societal perspective. Methods The annual cost of asthma was assessed in a Danish nationwide cohort of patients aged 18-45 during 2014-2016 as excess healthcare costs, loss of income and welfare expenditure compared with controls (matched 1:4) using national registries. Asthma severity was defined as mild-to-moderate (steps 1-3 or step 4 without exacerbations) or severe (step 4 with exacerbations or step 5). Results Across 63 130 patients (mean age 33, 55% female), the annual excess cost of asthma compared with controls was predicted to €4095 (95% CI €3856 to €4334) per patient. Beyond direct costs related to treatment and hospitalisations (€1555 (95% CI €1517 to €1593)), excess indirect costs related to loss of income (€1060 (95% CI €946 to €1171)) and welfare expenditure (eg, sick pay and disability pensions) (€1480 (95% CI €1392 to €1570)) were seen. Crude pooling of excess costs resulted in an annual societal cost of €263 million for all included patients. Severe asthma (4.5%) incurred 4.4 times higher net costs (€15 749 (95% CI 13 928 to €17 638)) compared with mild-to-moderate disease (€3586 (95% CI €3349 to €3824)). Furthermore, patients with severe asthma experienced an annual loss of income of €3695 (95% CI €4106 to €3225) compared with controls. Conclusion In young adults with asthma, a significant societal and individual financial burden of disease was seen across severities. Expenditure was mainly driven by loss of income and welfare utilisation, rather than direct healthcare costs.

Published
2023

96. Impact of Inititing Biologics in Patients With Severe Asthma on Long-term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER):Data From the International Severe Asthma Registry

Author

Chen, Wenjia, Tran, Trung N., Sadatsafavi, Mohsen, Murray, Ruth, Wong, Nigel Chong Boon, Ali, Nasloon, Ariti, Con, Bulathsinhala, Lakmini, Gil, Esther Garcia, FitzGerald, J. Mark, Alacqua, Marianna, Al-Ahmad, Mona, Altraja, Alan, Al-Lehebi, Riyad, Bhutani, Mohit, Bjermer, Leif, Bjerrum, Anne Sofie, Bourdin, Arnaud, von Bülow, Anna, Busby, John, Canonica, Giorgio Walter, Carter, Victoria, Christoff, George C., Cosio, Borja G., Costello, Richard W., Fonseca, João A., Gibson, Peter G., Yoo, Kwang Ha, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Iwanaga, Takashi, Jackson, David J., Jones, Rupert C., Koh, Mariko Siyue, Kuna, Piotr, Larenas-Linnemann, Désirée, Lehmann, Sverre, Lehtimäki, Lauri, Lyu, Juntao, Mahboub, Bassam, Maspero, Jorge, Menzies-Gow, Andrew N., Newell, Anthony, Sirena, Concetta, Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Perez-de-Llano, Luis, Perng (Steve), Diahn Warng, Peters, Matthew, Pfeffer, Paul E., Porsbjerg, Celeste M., Popov, Todor A., Rhee, Chin Kook, Salvi, Sundeep, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Ra, Seung Won, Wang, Eileen, Wechsler, Michael E., Price, David B., Chen, Wenjia, Tran, Trung N., Sadatsafavi, Mohsen, Murray, Ruth, Wong, Nigel Chong Boon, Ali, Nasloon, Ariti, Con, Bulathsinhala, Lakmini, Gil, Esther Garcia, FitzGerald, J. Mark, Alacqua, Marianna, Al-Ahmad, Mona, Altraja, Alan, Al-Lehebi, Riyad, Bhutani, Mohit, Bjermer, Leif, Bjerrum, Anne Sofie, Bourdin, Arnaud, von Bülow, Anna, Busby, John, Canonica, Giorgio Walter, Carter, Victoria, Christoff, George C., Cosio, Borja G., Costello, Richard W., Fonseca, João A., Gibson, Peter G., Yoo, Kwang Ha, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Iwanaga, Takashi, Jackson, David J., Jones, Rupert C., Koh, Mariko Siyue, Kuna, Piotr, Larenas-Linnemann, Désirée, Lehmann, Sverre, Lehtimäki, Lauri, Lyu, Juntao, Mahboub, Bassam, Maspero, Jorge, Menzies-Gow, Andrew N., Newell, Anthony, Sirena, Concetta, Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Perez-de-Llano, Luis, Perng (Steve), Diahn Warng, Peters, Matthew, Pfeffer, Paul E., Porsbjerg, Celeste M., Popov, Todor A., Rhee, Chin Kook, Salvi, Sundeep, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Ra, Seung Won, Wang, Eileen, Wechsler, Michael E., and Price, David B.

Abstract

Background Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone. Objective To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS. Methods This was a propensity score–matched, prospective cohort study using data from the International Severe Asthma Registry. Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCSs for ≥1 year or ≥4 courses of rescue OCSs within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with noninitiators. The impact of biologic initiation on asthma outcomes was assessed using generalized linear models. Results We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations per year versus noninitiators (0.64 vs 2.06; rate ratio, 0.27 [95% CI, 0.10-0.71]). Biologic initiators were 2.2 times more likely than noninitiators to take a daily long-term OCS dose of less than 5 mg (risk probability, 49.6% vs 22.5%; P = .002) and had a lower risk of asthma-related emergency department visits (relative risk, 0.35 [95% CI, 0.21-0.58]; rate ratio, 0.26 [0.14-0.48]) and hospitalizations (relative risk, 0.31 [95% CI, 0.18-0.52]; rate ratio, 0.25 [0.13-0.48]). Conclusions In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and health care resource utilization., Background: Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone. Objective: To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS. Methods: This was a propensity score–matched, prospective cohort study using data from the International Severe Asthma Registry. Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCSs for ≥1 year or ≥4 courses of rescue OCSs within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with noninitiators. The impact of biologic initiation on asthma outcomes was assessed using generalized linear models. Results: We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations per year versus noninitiators (0.64 vs 2.06; rate ratio, 0.27 [95% CI, 0.10-0.71]). Biologic initiators were 2.2 times more likely than noninitiators to take a daily long-term OCS dose of less than 5 mg (risk probability, 49.6% vs 22.5%; P = .002) and had a lower risk of asthma-related emergency department visits (relative risk, 0.35 [95% CI, 0.21-0.58]; rate ratio, 0.26 [0.14-0.48]) and hospitalizations (relative risk, 0.31 [95% CI, 0.18-0.52]; rate ratio, 0.25 [0.13-0.48]). Conclusions: In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and health care resource utilization.

Published
2023

97. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

Author

Pfeffer, Paul E., Ali, Nasloon, Murray, Ruth, Ulrik, Charlotte, Tran, Trung N., Maspero, Jorge, Peters, Matthew, Christoff, George C., Sadatsafavi, Mohsen, Torres-Duque, Carlos A., Altraja, Alan, Lehtimäki, Lauri, Papadopoulos, Nikolaos G, Salvi, Sundeep, Costello, Richard W., Cushen, Breda, Heffler, Enrico, Iwanaga, Takashi, Al-Ahmad, Mona, Larenas-Linnemann, Désirée, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Rhee, Chin Kook, Perez-de-Llano, Luis, Perng Steve, Diahn Warng, Mahboub, Bassam, Wang, Eileen, Goh, Celine, Lyu, Juntao, Newell, Anthony, Alacqua, Marianna, Belevskiy, Andrey S., Bhutani, Mohit, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Bulow, Anna von, Busby, John, Canonica, Giorgio Walter, Cosio, Borja G., Dorscheid, Delbert R., Muñoz-Esquerre, Mariana, FitzGerald, J. Mark, Gil, Esther Garcia, Gibson, Peter G., Heaney, Liam G., Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Jackson, David J., Koh, Mariko Siyue, Ko, Hsin Kuo Bruce, Lee, Jae Ha, Lehmann, Sverre, Chaves Loureiro, Cláudia, Lúðvíksdóttir, Dóra, Menzies-Gow, Andrew N., Mitchell, Patrick, Papaioannou, Andriana I., Popov, Todor A., Porsbjerg, Celeste M., Salameh, Laila, Sirena, Concetta, Taillé, Camille, Taube, Christian, Tohda, Yuji, Wechsler, Michael E., Price, David B., Pfeffer, Paul E., Ali, Nasloon, Murray, Ruth, Ulrik, Charlotte, Tran, Trung N., Maspero, Jorge, Peters, Matthew, Christoff, George C., Sadatsafavi, Mohsen, Torres-Duque, Carlos A., Altraja, Alan, Lehtimäki, Lauri, Papadopoulos, Nikolaos G, Salvi, Sundeep, Costello, Richard W., Cushen, Breda, Heffler, Enrico, Iwanaga, Takashi, Al-Ahmad, Mona, Larenas-Linnemann, Désirée, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Rhee, Chin Kook, Perez-de-Llano, Luis, Perng Steve, Diahn Warng, Mahboub, Bassam, Wang, Eileen, Goh, Celine, Lyu, Juntao, Newell, Anthony, Alacqua, Marianna, Belevskiy, Andrey S., Bhutani, Mohit, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Bulow, Anna von, Busby, John, Canonica, Giorgio Walter, Cosio, Borja G., Dorscheid, Delbert R., Muñoz-Esquerre, Mariana, FitzGerald, J. Mark, Gil, Esther Garcia, Gibson, Peter G., Heaney, Liam G., Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Jackson, David J., Koh, Mariko Siyue, Ko, Hsin Kuo Bruce, Lee, Jae Ha, Lehmann, Sverre, Chaves Loureiro, Cláudia, Lúðvíksdóttir, Dóra, Menzies-Gow, Andrew N., Mitchell, Patrick, Papaioannou, Andriana I., Popov, Todor A., Porsbjerg, Celeste M., Salameh, Laila, Sirena, Concetta, Taillé, Camille, Taube, Christian, Tohda, Yuji, Wechsler, Michael E., and Price, David B.

Abstract

Background Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. Methods This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R. The effectiveness of anti-IgE and anti-IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long-term-oral corticosteroid (LTOCS) use, asthma-related emergency room (ER) attendance, and hospital admissions. Results In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti-IL5/5R group and 38.7% in the anti-IgE group. Patients treated with anti-IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti-IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti-IL5/5R experienced fewer asthma-related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43). Conclusions In real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use., Background: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. Methods: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R. The effectiveness of anti-IgE and anti-IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long-term-oral corticosteroid (LTOCS) use, asthma-related emergency room (ER) attendance, and hospital admissions. Results: In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti-IL5/5R group and 38.7% in the anti-IgE group. Patients treated with anti-IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti-IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti-IL5/5R experienced fewer asthma-related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43). Conclusions: In real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.

Published
2023

98. A serologically assessed neo-epitope biomarker of cellular fibronectin degradation is related to pulmonary fibrosis

Author

Hummersgaard Hansen, Annika, Wallem Breisnes, Helene, Skovhus Prior, Thomas, Hilberg, Ole, Guldager Kring Rasmussen, Daniel, Genovese, Federica, Vestergaard Lukassen, Marie, Svensson, Birte, Løcke Langholm, Lasse, Manon-Jensen, Tina, Asser Karsdal, Morten, Julie Leeming, Diana, Bendstrup, Elisabeth, Marie Bülow Sand, Jannie, Hummersgaard Hansen, Annika, Wallem Breisnes, Helene, Skovhus Prior, Thomas, Hilberg, Ole, Guldager Kring Rasmussen, Daniel, Genovese, Federica, Vestergaard Lukassen, Marie, Svensson, Birte, Løcke Langholm, Lasse, Manon-Jensen, Tina, Asser Karsdal, Morten, Julie Leeming, Diana, Bendstrup, Elisabeth, and Marie Bülow Sand, Jannie

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is characterized by excessive extracellular matrix (ECM) remodeling, herein ECM degradation. Fibronectin (FN) is an important component of the ECM that is produced by multiple cell types, including fibroblasts. Extra domain B (EDB) is specific for a cellular FN isoform which is found in the ECM. We sought to develop a non-invasive test to investigate whether matrix metalloproteinase 8 (MMP-8) degradation of EDB in cellular FN results in a specific protein fragment that can be assessed serologically and if levels relate to pulmonary fibrosis. Method: Cellular FN was cleaved in vitro by MMP-8 and a protein fragment was identified by mass spectrometry. A monoclonal antibody (mAb) was generated, targeting a neo-epitope originating from EDB in cellular FN. Utilizing this mAb, a neo-epitope specific enzyme-linked immunosorbent assay (FN-EDB) was developed and technically validated. Serum FN-EDB was assessed in an IPF cohort (n = 98), registered at clinicaltrials.gov (NCT02818712), and in healthy controls (n = 35). Results: The FN-EDB assay had high specificity for the MMP-8 degraded neo-epitope and was technically robust. FN-EDB serum levels were not influenced by age, sex, ethnicity, or BMI. Moreover, FN-EDB serum levels were significantly higher in IPF patients (median 31.38 [IQR 25.79–46.84] ng/mL) as compared to healthy controls (median 28.05 [IQR 21.58–33.88] ng/mL, p = 0.023). Conclusion: We developed the neo-epitope specific FN-EDB assay, a competitive ELISA, as a tool for serological assessment of MMP-8 mediated degradation of EDB in cellular FN. This study indicates that degradation of EDB in cellular FN is elevated in IPF and warrants further investigation.

Published
2023

99. Exacerbations Predict Severe Cardiovascular Events in Patients with COPD and Stable Cardiovascular Disease–A Nationwide, Population-Based Cohort Study

Author

Løkke,Anders, Hilberg,Ole, Lange,Peter, Ibsen,Rikke, Telg,Gunilla, Stratelis,Georgios, Lykkegaard,Jesper, Løkke,Anders, Hilberg,Ole, Lange,Peter, Ibsen,Rikke, Telg,Gunilla, Stratelis,Georgios, and Lykkegaard,Jesper

Abstract

Anders Løkke,1,2 Ole Hilberg,1,2 Peter Lange,3,4 Rikke Ibsen,5 Gunilla Telg,6 Georgios Stratelis,6 Jesper Lykkegaard7 1Department of Medicine, Little Belt Hospital, Vejle, Denmark; 2Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; 3Medical Department, Copenhagen University Hospital-Herlev, Herlev, Denmark; 4Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark; 5i2Minds, Aarhus, Denmark; 6AstraZeneca Nordic, Södertälje, Sweden; 7Research Unit for General Practice, Institute of Public Health, University of Southern Denmark, Odense, DenmarkCorrespondence: Anders Løkke, Department of Medicine, Little Belt Hospital, Vejle, Denmark, Email Anders.Lokke@rsyd.dkObjective: Patients with chronic obstructive pulmonary disease (COPD) commonly present with cardiovascular disease (CVD). We investigated the association between COPD exacerbations and major cardiovascular (CV) events in a COPD population with a history of CVD.Methods: This population-based and register-based cohort study identified all Danish COPD patients aged ≥ 40 years who visited a hospital-based, pulmonary outpatient clinic for COPD between 1st January, 2010, and 31st December, 2016, from a nationwide COPD registry. Patients with a history of a major CV event 36‒6 months prior to their COPD measurement date and no CV event 6 months before this date were included. During a 6-month assessment period, the risks of a new CV event (hospitalization with fatal/non-fatal stroke, myocardial infarction, or heart failure) and moderate and severe COPD exacerbations were evaluated. Odds ratios with 95% confidence intervals for CV events and death were estimated using adjusted logistic regression models.Results: Of the 1501 COPD patients included, 55% experienced a COPD exacerbation and 13% experienced both an exacerbation and a CV event during follow-up (6 months). The odds of a CV event were 1.5 times higher in patients with a mod

Published
2023

100. Exacerbations Predict Severe Cardiovascular Events in Patients with COPD and Stable Cardiovascular Disease-A Nationwide, Population-Based Cohort Study

Author

Lokke, Anders, Hilberg, Ole, Lange, Peter, Ibsen, Rikke, Telg, Gunilla, Stratelis, Georgios, Lykkegaard, Jesper, Lokke, Anders, Hilberg, Ole, Lange, Peter, Ibsen, Rikke, Telg, Gunilla, Stratelis, Georgios, and Lykkegaard, Jesper

Abstract

Objective: Patients with chronic obstructive pulmonary disease (COPD) commonly present with cardiovascular disease (CVD). We investigated the association between COPD exacerbations and major cardiovascular (CV) events in a COPD population with a history of CVD. Methods: This population-based and register-based cohort study identified all Danish COPD patients aged ≥ 40 years who visited a hospital-based, pulmonary outpatient clinic for COPD between 1st January, 2010, and 31st December, 2016, from a nationwide COPD registry. Patients with a history of a major CV event 36‒6 months prior to their COPD measurement date and no CV event 6 months before this date were included. During a 6-month assessment period, the risks of a new CV event (hospitalization with fatal/non-fatal stroke, myocardial infarction, or heart failure) and moderate and severe COPD exacerbations were evaluated. Odds ratios with 95% confidence intervals for CV events and death were estimated using adjusted logistic regression models. Results: Of the 1501 COPD patients included, 55% experienced a COPD exacerbation and 13% experienced both an exacerbation and a CV event during follow-up (6 months). The odds of a CV event were 1.5 times higher in patients with a moderate exacerbation and more than 6-times higher in those with a severe exacerbation vs patients with no exacerbation(s). The majority of CV events occurred within 30 days post exacerbation in patients who experienced both an exacerbation and a CV event. In total, 113 patients died during the study period: 28% of deaths were caused by CVD and 72% by reasons other than CVD, mostly COPD. Conclusion: In patients with known CVD, severe COPD exacerbations are associated with increased odds of major CV events that occur within 30 days post exacerbation, highlighting the need to prevent exacerbations in COPD patients with concomitant CVD to potentially improve both respiratory and CV health. Keywords: concomitant cardiovascular dis, Objective: Patients with chronic obstructive pulmonary disease (COPD) commonly present with cardiovascular disease (CVD). We investigated the association between COPD exacerbations and major cardiovascular (CV) events in a COPD population with a history of CVD.Methods: This population-based and register-based cohort study identified all Danish COPD patients aged >= 40 years who visited a hospital-based, pulmonary outpatient clinic for COPD between 1st January, 2010, and 31st December, 2016, from a nationwide COPD registry. Patients with a history of a major CV event 36-6 months prior to their COPD measurement date and no CV event 6 months before this date were included. During a 6-month assessment period, the risks of a new CV event (hospitalization with fatal/ non-fatal stroke, myocardial infarction, or heart failure) and moderate and severe COPD exacerbations were evaluated. Odds ratios with 95% confidence intervals for CV events and death were estimated using adjusted logistic regression models.Results: Of the 1501 COPD patients included, 55% experienced a COPD exacerbation and 13% experienced both an exacerbation and a CV event during follow-up (6 months). The odds of a CV event were 1.5 times higher in patients with a moderate exacerbation and more than 6-times higher in those with a severe exacerbation vs patients with no exacerbation(s). The majority of CV events occurred within 30 days post exacerbation in patients who experienced both an exacerbation and a CV event. In total, 113 patients died during the study period: 28% of deaths were caused by CVD and 72% by reasons other than CVD, mostly COPD.Conclusion: In patients with known CVD, severe COPD exacerbations are associated with increased odds of major CV events that occur within 30 days post exacerbation, highlighting the need to prevent exacerbations in COPD patients with concomitant CVD to potentially improve both respiratory and CV health.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results